These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37753224)

  • 1. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
    Konkle BA; Oldenburg J; Pasi J; Kulkarni R; Nolan B; Mahlangu J; Young G; Brown SA; Pabinger I; Shapiro A; Négrier C; Blanchette V; Ragni MV; Dumont J; Lethagen S
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102180. PubMed ID: 37753224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.
    Nolan B; Mahlangu J; Pabinger I; Young G; Konkle BA; Barnes C; Nogami K; Santagostino E; Pasi KJ; Khoo L; Winding B; Yuan H; Fruebis J; Rudin D; Oldenburg J
    Haemophilia; 2020 May; 26(3):494-502. PubMed ID: 32227570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
    Álvarez-Román MT; Shapiro AD; Ragni MV; Palmborg H; Bystrická L; Szamosi J; Casiano S; Chambost H
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102163. PubMed ID: 37720484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.
    Bidlingmaier C; Heller C; Langer F; Miesbach W; Scholz U; Oldenburg J; Nüesch E; Palmborg H; Santagostino E; Tiede A
    Res Pract Thromb Haemost; 2024 Jul; 8(5):102482. PubMed ID: 39101128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
    Shapiro AD; Kulkarni R; Ragni MV; Chambost H; Mahlangu J; Oldenburg J; Nolan B; Ozelo MC; Foster MC; Willemze A; Barnowski C; Jain N; Winding B; Dumont J; Lethagen S; Barnes C; Pasi KJ
    Blood Adv; 2023 Jul; 7(13):3049-3057. PubMed ID: 36848635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.
    Oldenburg J; Kulkarni R; Srivastava A; Mahlangu JN; Blanchette VS; Tsao E; Winding B; Dumont J; Jain N
    Haemophilia; 2018 Jan; 24(1):77-84. PubMed ID: 29082639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
    Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
    Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
    J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
    Hakimi Z; Santagostino E; Postma MJ; Nazir J
    Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.
    Chowdary P; Holmström M; Mahlangu JN; Ozelo MC; Pabinger I; Pasi KJ; Ragni MV; Shapiro A; Barnowski C; Lethagen S
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12760. PubMed ID: 35910942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results.
    Königs C; Ozelo MC; Dunn A; Kulkarni R; Nolan B; Brown SA; Schiavulli M; Gunawardena S; Mukhopadhyay S; Jayawardene D; Winding B; Carcao M
    Blood; 2022 Jun; 139(26):3699-3707. PubMed ID: 35421219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
    Shrestha A; Su J; Li N; Barnowski C; Jain N; Everson K; Jena AB; Batt K
    Res Pract Thromb Haemost; 2021 Jan; 5(1):94-103. PubMed ID: 33537533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate
    Chowdary P; Fosbury E; Riddell A; Mathias M
    J Blood Med; 2016; 7():187-198. PubMed ID: 27695377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.